UNSPSC 51371507: Lefetamine hydrochloride

This classification denotes an analgesic agent with the molecular formula C16H19N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XYT5RKF8JA, chemically known as (-)-n,n-dimethyl-1,2-diphenylethylamine hydrochloride, but more generally known as lefetamine hydrochloride, which bears US NIH Compound Identifier 26480. European Medicines Agency schedules lefetamine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08423MIG.

Most nations, for tariff purposes, schedule lefetamine hydrochloride under HS 29214600. SMILES: CN(C)[C@H](CC1CCCCC1)C2CCCCC2.CL.

UNSPSC 51371507 Lefetamine hydrochloride is a Commodity code that in practice does not align with recent state and local procurement activity under its designation. The code shows no recent solicitations for lefetamine hydrochloride itself; the three most recent opportunities tagged to this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals through a cooperative purchasing vehicle—none of which concern lefetamine. State and local issuing bodies use this code nominally for pharmaceutical supply contracting, but the actual purchasing pattern reflects broader pharmacy benefit and public health initiatives rather than this specific pharmaceutical ingredient.

Recent activity spans Florida county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure naloxone and drug deactivation systems annually through quarterly deliveries, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, with responses due March 26, 2026 and contract effectiveness July 1, 2026. The code sees activity in Florida and Minnesota with regional impact through cooperative purchasing. Given the misalignment between the code's nominal scope and actual recent procurement content, this code does not represent a meaningful pursuit opportunity for vendors in the lefetamine supply space.